Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment
Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with t...
Saved in:
Main Authors: | Francesca Conti, Mattia Moratti, Elena Sabattini, Pier Luigi Zinzani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517543/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
by: María Reyes Abad, et al.
Published: (2025-01-01) -
Interfollicular Hodgkin’s lymphoma: A diagnostic challenge for pathologists
by: Maneesh K. Vijay, et al.
Published: (2023-03-01) -
Technical studies about the prestressed insulation cylinder of HL-3 tokamak's center-post
by: Yin Qiu, et al.
Published: (2025-01-01) -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW
by: Maria Luisa Moleti, et al.
Published: (2024-10-01) -
Implementing deep learning-based disruption prediction in a drifting data environment of new tokamak: HL-3
by: Zongyu Yang, et al.
Published: (2025-01-01)